Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Getting a diagnosis

Topic: Risk, prevention and care in population studies

Plain-language summary

Introduction Rapid growth of the older adult population requires greater epidemiologic characterization of dementia. We developed national prevalence estimates of diagnosed dementia and subtypes in the highest risk United States (US) population. Methods We analyzed Centers for Medicare & Medicaid administrative enrollment and claims data for 100% of Medicare fee-for-service beneficiaries enrolled during 2011-2013 and age ≥68 years as of December 31, 2013 (n = 21.6 million). Results Over 3.1 million (14.4%) beneficiaries had a claim for a service and/or treatment for any dementia subtype. Dementia not otherwise specified was the most common diagnosis (present in 92.9%). The most common subtype was Alzheimer's (43.5%), followed by vascular (14.5%), Lewy body (5.4%), frontotemporal (1.0%), and alcohol induced (0.7%). The prevalence of other types of diagnosed dementia was 0.2%. Discussion This study is the first to document concurrent prevalence of primary dementia subtypes among this US population. The findings can assist in prioritizing dementia research, clinical services, and caregiving resources.

What this study adds

Evidence grade: Low

The record lists 21 participants. Among 21.6 million Medicare fee-for-service beneficiaries, 14.4% had a claim for any dementia subtype, with Alzheimer's the most common subtype at 43.5%. Reported effect size: 14.4%; 92.9%; 43.5%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Goodman, R. A., Lochner, K. A., Thambisetty, M., Wingo, T. S., Posner, S. F., & Ling, S. M. (2017). Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011-2013. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1016/j.jalz.2016.04.002

Vancouver

Goodman RA, Lochner KA, Thambisetty M, Wingo TS, Posner SF, Ling SM. Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011-2013. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2017. doi:10.1016/j.jalz.2016.04.002. PMID: 27172148.

BibTeX

@article{goodman2017-27172148,
  author  = {Goodman, R. A. and Lochner, K. A. and Thambisetty, M. and Wingo, T. S. and Posner, S. F. and Ling, S. M.},
  title   = {{Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011-2013}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2017},
  doi     = {10.1016/j.jalz.2016.04.002},
  pmid    = {27172148},
  url     = {https://doi.org/10.1016/j.jalz.2016.04.002}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

Among 21.6 million Medicare fee-for-service beneficiaries, 14.4% had a claim for any dementia subtype, with Alzheimer's the most common subtype at 43.5%. This is a count of diagnosed cases and provides no information on treating, curing or preventing Alzheimer's disease.

Study details

How this study scored 59/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 1 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 6 of 7; Citations per year 4 of 5; Impact for its field and year 4 of 6; Cited by studies here 3 of 6; Still being cited 3 of 4; Senior author's track record 2 of 4; Institution's track record 3 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 59 of 100.59 of 100 points earned41 not earned

Published in a leading specialty journal. Scored zero for study design and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2017 — within 10 year(s) of the newest study here
Sample size 1 / 4 21 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 328 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 29.8 citations a year over 11 year(s) since 2017
Impact for its field and year 4 / 6 Cited 14.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 28 other studies in this library
Still being cited 3 / 4 Cited 93 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Shari M. Ling: h-index 36 (OpenAlex, whole career)
Institution's track record 3 / 3 National Institutes of Health: institution h-index 2,723 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 7 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 27172148)
Free to read 0 / 2 Behind a paywall — scores zero
Total 59 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 19.

Later studies that cite this one

28 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Getting a diagnosis from nearby years

Also tagged “prevalence”

1,224 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,224 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Getting a diagnosis

See all studies in Getting a diagnosis →